👁️ HEALTH ON THE FRONT LINE

Special Coverage · February 26, 2026 · Vall d'Hebron Research Institute · Barcelona

 

📅  OPHTHALMOLOGY · DIABETES · BIOTECHNOLOGY

Eye drops can change the fate of 537 million diabetics: D-Sight starts the world's first clinical trial to treat retinopathy in its earliest stages

For 15 years, doctors Rafael Simó and Cristina Hernández quietly investigated a mechanism that no one took seriously: neurodegeneration of the retina occurs before any visible vascular damage appears. Today, its spin-off D-Sight is weeks away from confirming in humans that a simple eye drop with sitagliptin can slow down that process. If they succeed, they will have opened a therapeutic window that did not exist anywhere in the world.

 

🌍 537M people with diabetes in the world

👁️ ~30% of diabetics develop retinopathy

🚫 0 Treatments for early stages

 

Source: IDF Diabetes Atlas 2025 / VHIR / D-Sight

 

 

🔍  THE INVISIBLE DISEASE THAT STEALS VISION

 

Diabetic retinopathy is one of the great silent tragedies of modern medicine. It settles in painlessly, without symptoms in its early stages, and moves methodically until it causes irreversible damage. It is the most common microvascular complication of diabetes and the leading preventable cause of visual impairment and blindness in people of working age worldwide. In concrete numbers: it affects approximately 30% of patients with type 2 diabetes and practically all type 1 diabetics with more than 20 years of evolution.

The mechanism that guided all research for decades was vascular: diabetes damages the blood vessels of the retina, causes microaneurysms, hemorrhages, exudates and finally macular edema or pathological vascular proliferation. From this paradigm, the available treatments are photocoagulator laser and intravitreal injections of anti-VEGF drugs, both highly invasive, expensive interventions, with frequent adverse effects and only applied when the disease has already caused serious structural damage.

"There are currently no therapeutic options for the earliest stages of diabetic retinopathy. We are facing an unmet medical need on a global scale." — Carla Maté Goldar, CEO and co-founder of D-Sight

 

What no one had been able to do until now was to intervene in the initial stages, when the diagnosis is recent and the damage is still reversible. The cause: the scientific community did not have a clear therapeutic target in that window. There was no way to act because there was no recognized mechanism to act. Until the VHIR team demonstrated something that changed the field: neurodegeneration of the retina precedes microvascular involvement.

 

💡  THE FINDING THAT CHANGED THE PARADIGM: NEURO BEFORE VASCULAR

 

The scientific history of D-Sight begins more than 15 years ago in the Diabetes and Metabolism Research Group of the Vall d'Hebron Research Institute (VHIR), led by Dr. Rafael Simó, head of the Endocrinology and Nutrition Service at Vall d'Hebron University Hospital. Together with Dr. Cristina Hernández, Simó developed a line of research that challenged the dominant vascular paradigm: the retina is not only a vascular tissue, but a specialized neural tissue.

The hypothesis, then controversial, was gaining evidence: in the preclinical stages of diabetic retinopathy, before the first detectable ophthalmological signs appear, there is already loss of retinal ganglion cells, reduction in the thickness of the nerve fiber and alterations in the function of the optic nerve. Neurodegeneration precedes and partly drives vascular damage. If you can stop this neural process from the beginning, you can prevent the cascade of damage that culminates in blindness.

"It has taken us 15 years to convince the scientific community that retinal neurodegeneration precedes microvascular involvement. Now there is no longer any doubt." — Dr. Rafael Simó, Scientific Co-Founder of D-Sight and Head of the Diabetes and Metabolism Group, VHIR

 

The next challenge was to find the drug capable of exerting this neuroprotection in a safe, effective and accessible way. After years of screening, the answer was surprising to many: sitagliptin, a DPP-4 enzyme inhibitor already widely used as an oral antidiabetic, proved to be the most potent, cost-efficient candidate with the highest margin of safety for topical ocular application. The finding opened an unexpected avenue: pharmacological repurposing, that is, a drug already approved in another indication, now reformulated as eye drops for a completely new use.

 

🏢  D-SIGHT: FROM PUBLIC RESEARCH TO THE GLOBAL MARKETPLACE

 

D-Sight was set up as a spin-off of VHIR under an innovative 'entrepreneur in residence' model, the first in the history of the Catalan institute. Carla Maté Goldar, an expert in knowledge transfer and scientific entrepreneurship, took on the role of CEO and co-founder, providing the entrepreneurial dimension that researchers needed to make the leap from the laboratory to the market.

The company is currently developing two main lines: sitagliptin eye drops for diabetic retinopathy in early stages – its priority asset – and a second neuroprotective candidate for glaucoma, a pathology that shares the mechanism of optic nerve damage but already has existing treatments, although limited to reducing intraocular pressure without offering real neuroprotection.

 

💰 FUNDING STRUCTURE 💼 Clave Capital (Clave Innohealth): Continuous private investment since incorporation. He leads the last round. [Lead Investor] 🏛️ CPP 2024 Programme — Spain: 1.5 million euros — Public-Private Partnership Call. [Public funding] 🔬 Prous Institute for Biomedical Research: New strategic partner in AI and life sciences. [Strategic Investor] 📊 Total raised: €5 million accumulated (last round: €2 million in 2026). [Milestone 2026]

 

The planned business model is to license a large multinational pharmaceutical company for global commercialization, once D-Sight has completed the clinical validation phases. The company expects to reach the market in the period 2032-2033, a horizon that Maté describes as 'moderately optimistic' but adjusted to the usual times of international pharmaceutical regulation.

 

🧬  THE PHASE I CLINICAL TRIAL: WHAT WILL BE TESTED

 

The study that will begin in the coming weeks is a Phase I clinical trial, the first step of clinical development in humans. Their goal is not to prove that eye drops cure diabetic retinopathy, but something more basic and fundamental: to confirm that it is safe. The trial will administer the ophthalmic formulation of sitagliptin to healthy volunteers and assess its tolerability, absorption, and absence of local and systemic adverse effects.

The Spanish Agency for Medicines and Health Products (AEMPS) has already advanced in the regulatory process, and D-Sight completed the industrial scale-up studies necessary to produce the drug with the GMP (Good Manufacturing Practice) standards required for human trials. The horizon to complete this phase is 2026 itself, with expected results in the second half of the year.

 

#	STAGE	OBJECTIVE AND CONTENT	STATE
🔬	Phase I (2026)	Healthy volunteers — Safety and tolerability of sitagliptin in eye drops. No expected toxicity according to animal models.	🟢 ONGOING
🧪	Phase II (2026–2027)	Patients with early diabetic retinopathy — Clinical efficacy, optimal dose, and biomarkers of response.	🟡 PLANNED
📊	Phase III (2028–2030)	Multicenter pivotal trial — Confirmation of efficacy and safety profile on a large scale for regulatory registration.	⚪ FUTURE
💊	Market (2032–2033)	Global commercialization with a multinational pharmaceutical partner through an operating license.	⚪ FUTURE

Source: D-Sight / VHIR / Medical Writing, February 2026

 

The choice of healthy volunteers for Phase I is standard in pharmaceutical development: it is about evaluating safety without exposing patients with active pathology to a non-validated drug. Researchers are especially confident in the tolerability of the compound given that sitagliptin has an extensive history of oral use without major adverse effects, and the formulation as eye drops—locally administered and topographically confined—minimizes systemic absorption.

The most relevant aspect for patients is that the Phase I trial is not the final destination: it is the starting point for Phase II efficacy in patients with early diabetic retinopathy, scheduled for the same year 2026. At that stage, it will be confirmed whether eye drops effectively slow down retinal neurodegeneration in real patients.

"This study is the first step in validating the therapeutic potential of the drug and moving towards future phases of research in patients with diabetic retinopathy." — Dr. Rafael Simó, VHIR

 

 

📊  ADVANTAGES OVER CURRENT TREATMENTS

 

To understand the magnitude of the breakthrough represented by sitagliptin eye drops, it is necessary to compare it with the therapeutic arsenal currently available. Existing treatments share a characteristic that limits them structurally: they can only act when the disease has already progressed to intermediate or advanced stages.

 

TREATMENT	STADIUM	INVASIVENESS	EF. ADVERSE	ADMIN ROUTE.
Current treatment (laser)	Advanced stages only	High	Yes	Surgery/Hospital
Anti-VEGF (injection)	Advanced stages only	High	Frequently Asked	Intravitreal injection
Sitagliptin eye drops (D-Sight)	Early phases ✅	Very low	Unexpected	Self-administered ✅

Source: VHIR / D-Sight / own elaboration

 

🎯 The decisive factor: D-Sight eye drops are the only candidate in development capable of acting at the time of diabetes diagnosis, before any clinical signs of eye involvement appear. It does not require hospital infrastructure, can be self-administered at home and its production cost is significantly lower than that of anti-VEGF biologics.

 

🔵  THE SECOND FRONT: GLAUCOMA

 

The Phase I clinical trial is 'useful for both indications', according to Dr. Simó. In addition to diabetic retinopathy, the same molecule is being developed as a neuroprotective therapy for glaucoma. This distinction is important: in glaucoma there are already eye drops on the market, but they all act by reducing intraocular pressure, without offering direct protection to the neurons of the optic nerve. D-Sight targets that therapeutic gap with its neuroprotective formulation.

The advantage is that the glaucoma research base can advance at a faster pace, by sharing the mechanism of action with the already more mature retinopathy program. The dual Phase I will allow relevant safety data to be obtained for both indications simultaneously, shortening the development times of the second candidate.

 

🌐  THE CONTEXT: A SILENT DIABETES PANDEMIC

 

The epidemiological context makes D-Sight's success not just a scientific milestone: it is a public health emergency. The International Diabetes Federation (IDF) estimates that in 2025 there are 537 million people with diabetes in the world, a figure that could reach 643 million in 2030 and 783 million in 2045. Most live in low- and middle-income countries, where access to current expensive and invasive retinopathy treatments is virtually non-existent.

A low-cost, self-administerable eye drop that can be applied from the initial diagnosis of diabetes would radically transform the preventive approach to diabetic blindness on a global scale. Spain, through VHIR and D-Sight, is positioned on the frontier of this transformation. The Vall d'Hebron Hospital, recognized as the 20th best hospital in the world and the first in Spain in its specialty according to Newsweek, endorses the institutional solidity behind the project.

 

 

👁️

15 years of research that no one believed, now weeks away from being tested on humans.

If eye drops work, millions of people around the world will have the chance to preserve their vision for the first time before losing it.

 

 

Sources: Vall d'Hebron Research Institute (VHIR) · D-Sight · ConSalud.es · Medical Writing · Action Vision Spain · InfoDiabetic · Biotech Spain · InnovaSpain · The Referent · IDF Diabetes Atlas 2025

 

🤖 ROBOTS ON THE WORLD'S BIGGEST STAGE

The Great Leap of Chinese Humanoids: How Unitree Robotics Redefined the Boundaries of Robotics in Front of 679 Million People

Beijing · 16 de febrero de 2026  Fuentes: CNBC · South China Morning Post · The Guardian · Fox News · Daily Mail · TechEBlog · Interesting Engineering

On the most-watched night of the year in China – and one of the most watched on the planet – dozens of humanoid robots from the Hangzhou company Unitree Robotics burst onto the stage of the 2026 Spring Festival Gala to execute, completely autonomously, a martial arts choreography that broke five world records and revealed that humanoid robotics is no longer a promise of the laboratory:  it is an industry.

 

📺 679 M Telecommunications

🤖 ~300 G1 robots on stage

⚡ 4 m/s Maximum speed

💰 $13,500 G1 base price

 

📺  THE SETTING: CHINA'S SUPER BOWL

The China Media Group Spring Festival Gala — popularly known as the Chunwan — is the world's most-watched television program consistently since the 1980s. Its annual audience is around 700 million viewers and easily surpasses the American Super Bowl or the final of the World Cup. For a tech company, appearing on that stage is tantamount to a public demonstration of capabilities to the world's largest global market.

On Monday, February 16, 2026, as the Year of the Horse began, Unitree Robotics starred in the most talked-about segment of the night under the name

Wu Bot ("Real CyberKung Fu"). Dozens of G1 units — the company's most commercially popular humanoid — took center stage in Beijing and performed a martial arts choreography synchronized with a group of children from the famous Tagou School of Martial Arts.

 

"It was the whole world watching, and the robots knew it perfectly. They didn't miss a single move." — Guardian Chronicle, February 17, 2026

 

What the audience saw that night—moving swords, spinning nunchucks, trampoline jumps, and coordinated runs—wasn't simply a spectacle. It was the most massive demonstration to date that autonomous humanoid robotics can operate under extreme pressure conditions, in front of a global audience and with no room for error.

🏆  THE FIVE SINGLE-NIGHT WORLD RECORDS

According to the technical data published by Unitree in its official statement and confirmed by specialized media such as TechEBlog, Interesting Engineering and The AI Insider, the performance on February 16 established the following unprecedented milestones in the history of humanoid robotics:

 

	GLOBAL BRAND	TECHNICAL DETAIL
🦘	Trampoline jump: 3 meters	First time a humanoid robot has reached this height in an autonomous jump. Complete series of stunts were executed.
💨	Carrera: 4 m/s (14.4 km/h)	Stage-coordinated cluster speed. It is equivalent to a sustained human trot.
🌀	Airflare: 7.5 rotations	First time achieved by any humanoid platform in the world. Outperforms previous competitor demos.
🗡️	Handling of real weapons	Swords, clubs and nunchucks with new generation dexterous hands, with more than 90% accuracy in learned sequences.
⏱️	Synchronization: hundredths of a second	The robots coordinated movements with each other and with the child artists with minimal latency in real time.

 

Behind each of these achievements is a radically updated motion control system. Unitree implemented reinforcement learning combined with hybrid force-position control, and developed a new AI fusion localization algorithm that integrates proprioceptive data with three-dimensional LiDAR data to maintain positioning accuracy even during high-speed dynamic movements.

   Fuente técnica: The AI Insider / Unitree Official Release, 17/02/2026

⚙️  INSIDE THE ROBOT: THE TECHNOLOGY THAT MAKES IT POSSIBLE

🧠 The Brain: Real-Time Motion AI

What sets the G1 apart from previous generations is not only the mechanical power, but the software architecture that controls it. Wang Xingxing, founder and CEO of Unitree, explained to the Chinese media 36Kr that this year's technical focus was to ensure that robots could complete formation changes and movement transitions while running at high speed — something that no humanoid system had managed to do in a stable and coordinated way.

To do this, a high-concurrency cluster control system was developed capable of synchronizing dozens of robots in real time with minimal latency. Each unit simultaneously processes signals from its environment (triangular 3D LiDAR) and its own body (proprioceptive sensors) to adjust its position and movement in fractions of a second, without centralized communication that could introduce delay.

 

"Our robots can execute Kung Fu because we solved the problem of high-speed movement with formation accuracy. That same problem exists in factories." — Wang Xingxing, CEO de Unitree, 36Kr, 17/02/2026

 

🦾 The body: the G1 in numbers

SPECIFICATION	VALUE	RELEVANCE
Height	1.27 meters	Full human scale for work environments
Weight	35 kg (with battery)	Lightweight for logistics and handling tasks
Degrees of freedom	23 motorized joints	High mobility for complex motor tasks
By máximo de rodilla	90 N.m	Withstands high-impact loads and movements
Hands	Dextéras, new generation	Handling of tools, objects and weapons
Base price	USD 13,500 (int'l)	CNY 85,000 in China; Competitive vs Rivals

 

   Fuente: Unitree Robotics · TechEBlog · South China Morning Post

📈  THE DAY AFTER: ORDERS, PRICES AND OUTLOOK

The commercial impact was immediate and forceful. On the e-commerce platform JD.com, the closest delivery dates for the G1 were changed to the beginning of March in a few hours, with tens of thousands of visits to the product in the three days following the broadcast, according to data from the portal itself.

   Source: South China Morning Post, 20/02/2026

Wang Xingxing told the specialized media 36Kr, minutes after the end of the gala, that Unitree plans to ship between 10,000 and 20,000 units during 2026. This represents a growth of between 82% and 264% compared to the approximately 5,500 units shipped in 2025, and would make the company the manufacturer of humanoid robots with the highest production volume in the world.

   Fuente: South China Morning Post · CNBC, 17-20/02/2026

 

"The improvement in capacity compared to the previous year is between 5 and 10 times. And this is just the beginning." — CEO of Unitree, quoted by Daily Mail

 

The projection places Unitree in an unprecedented position in the industry. While Tesla has not yet set a price or general availability date for its Optimus robot, and while Boston Dynamics maintains Atlas as a research platform with no sales price, the G1 is already in inventory, with delivery in weeks.

🌐  THE MAP OF GLOBAL COMPETITION

The performance at the 2026 gala was not just one company's success: it was the strongest signal to date of the systemic advancement of Chinese humanoid robotics. Along with Unitree, three other companies — Galbot, Noetix and MagicLab — also appeared on the broadcast, in what analysts interpret as a coordinated demonstration of the national robotic ecosystem, with implicit backing from the Beijing government.

 

Company	Model	Price	Commercial status	Shipments 2026
🇨🇳 Unitree	G1 / H2	USD 13,500 / 29,900	For sale · Immediate deliveries	10,000–20,000 u.
🇺🇸 Tesla	Optimus	No public price	No general availability	Limited production
🇺🇸 Boston Dynamics	Atlas	No public price	Research Platform Only	No data
🇨🇳 Noetix	Bumi / N2	No public price	Prototype + gala 2026	No data

 

Unitree's competitive advantage lies in the combination of three factors: the Chinese manufacturing supply chain, which significantly reduces component costs, the state support for the humanoid robotics sector included in the 14th Five-Year Plan, and a go-to-market strategy that prioritizes actual availability over laboratory exclusivity.

   Source: CNBC · The Guardian · mlq.ai

🏭  BEYOND THE SHOW: WHAT DOES IT MEAN FOR THE INDUSTRY?

Wang Xingxing was explicit about it: the goal is not entertainment. Every movement demonstrated on the Chunwan stage has a direct equivalent in an industrial application. The dynamic balancing capabilities developed for trampoline jumps are the same as those needed for a robot to navigate uneven terrain in a logistics warehouse. The manual dexterity used to handle nunchucks and swords is the same as that required to assemble delicate components on a manufacturing line.

The CEO also estimated that the general capacity of the G1 robot is, today, comparable to that of a 10-year-old child – capable of performing complex motor tasks but still with limitations in reasoning and adaptation to unforeseen situations. Large-scale industrial utility, he said, would arrive in three to five years.

   Fuente: TechNode · 36Kr, 21/02/2026

Researchers consulted by CNBC stress that the demonstration of multi-robot coordination is perhaps the most relevant advance for real applications: in manufacturing environments, robots do not operate alone. The ability to synchronize dozens of units in real-time, without centralized communication, could be the key to fully automated assembly lines in high-turnover industries.

 

"The live performance in front of 679 million people was the biggest stress test ever given to a robot. He passed it." — Interesting Engineering, 18/02/2026

 

📌  CONCLUSION

The night of February 16, 2026 will be recorded in the history of technology as the moment when humanoid robotics definitively left the laboratory and entered the global stage. Not as a promise, but as a product. Not in a controlled demo, but in front of the largest television audience in the world.

Unitree Robotics didn't just break five world records that night. It showed that China has, today, the best commercially available humanoid robots on the planet, at the most competitive price, with the largest announced production volume and with the most massive validation that can exist: 679 million witnesses.

The race for the industrial humanoid has begun. And the first gunslinger is already on the track.

 

SOURCES CONSULTED

CNBC · South China Morning Post · The Guardian · Daily Mail · Fox News · TechEBlog · The AI Insider · Interesting Engineering · TechNode · mlq.ai · Unitree Robotics Official Release · 36Kr · Robozaps

🧬 GENOMICS — CEREALS — FOOD SECURITY

Scientists from CONICET and INTA identified two genomic regions that control the fertility of the wheat ear. The favorable allele increases yield by 5% and grains per square meter by 8%. The data is public and is already of interest to seed companies.

By Scientific Staff —  Sunday, February 22, 2026   ⏱ Read: 6 min

Published in: Field Crops Research   • Authors: Nicole Pretini (INTA Pergamino), Fernanda González (CONICET / CIT NOBA), Leonardo Vanzetti (INTA Marcos Juárez)

 

More than fifteen years ago, a group of Argentine scientists asked themselves a question that seemed simple but hid an enormous complexity: why do some ears of wheat produce more grains than others? The answer, forged between laboratories and batches in Buenos Aires, has just been published in the specialized journal Field Crops Research and is already resonating in the most important seed companies in the country: there is a region of the wheat genome that, when it carries the correct allele, improves yield by up to 5% and the number of grains per square meter by 8%.

The finding is the work of Nicole Pretini, researcher at INTA Pergamino and first author of the study; Fernanda González, CONICET researcher at CIT NOBA (Center for Research and Transfer of the Northwest of the Province of Buenos Aires) and INTA Pergamino; and Leonardo Vanzetti, from INTA Marcos Juárez, Córdoba. The three have been working for decades on the reproductive efficiency of the ear as a key to multiplying Argentine wheat production.

 

📊 RESEARCH IN FIGURES

 

🌾 19M ton ANNUAL PRODUCTION IN ARGENTINA

📈 5 % HIGHER YIELD (FAVORABLE ALLELE)

🧬 8 % MORE GRAINS PER M² (QTL QFFE. PERG-5A)

 

🔬 THE FINDING

Two genomic markers, a productive leap

QTLs (Quantitative Trait Loci) are regions of the genome that span several genes and are associated with observable quantitative characteristics, such as the height of a plant or, in this case, the number of grains produced by an ear. The team identified and validated two of these regions in real field conditions:

🧬 THE TWO QTLS IDENTIFIED 🟢  QFFE.perg-5A: the most powerful. When it carries the favorable allele, it consistently improves yield in all evaluated environments: +8% in grains per m² and +5% in total yield. 🟡  QFEm.perg-3A: Its effect is dependent on the environment, suggesting interaction with specific climatic or soil conditions.

 

The name 'QFFE' comes from the acronym for Spike Fruiting Efficiency, the conceptual axis of this entire line of research. What makes QFFE.perg-5A special is not only that it improves performance, but that it does so in two simultaneous ways: the individual ears produce more grains and, at the same time, there are more ears per square meter.

"In addition, we were able to establish that this improvement was a consequence not only of greater reproductive efficiency of the ears but also of the establishment of more ears per m²," Pretini said. The combined effect of both mechanisms is what makes this marker a high-value target for breeding programs.

 

"Under these conditions we observed that QTL QFFE.perg-5A affected performance in all the environments studied. Not only were there more efficient dowels, but also more dowels per square metre." — Nicole Pretini — INTA Pergamino, first author of the study

 

🌿 FROM THE LABORATORY TO THE FIELD

The Missing Test: Full-Scale Trials

Identifying a genomic region under controlled conditions is one thing. Showing that its effect is sustained when wheat is grown in a real field—with wind, climatic variations, competition between plants, and heterogeneous soils—is another story. That's exactly what the team did at this stage of research: bring the previous findings into the field.

The assays were carried out in multiple environments, using isogenic lines (genetically identical plants except in the region under study). The result was conclusive for QFFE.perg-5A: the favorable allele showed consistent improvements regardless of location, season, or soil conditions. This environmental robustness is, for specialists, a fundamental quality in a marker intended to be used in genetic improvement programs.

"Ear fertility or fruiting efficiency (FE, grains per g of ear dry weight at anthesis) was proposed as a promising trait to improve wheat yield potential, based on its functional relationship with the determination of grain number and evidence of trait variability in elite germplasm adapted to Argentina's productive conditions,"  González explained at the time of publication of the work.

 

👩 🔬 THE TEAM BEHIND THE DISCOVERY

 

🔬 Nicole Pretini Researcher — first author INTA Pergamino / CONICET	🌾 Fernanda González Director of the study CONICET CIT NOBA / INTA Pergamino
🧬 Leonardo Vanzetti Molecular Biology INTA Marcos Juárez (Córdoba)	🎓 Giuliana Ferrari Doctoral Fellow R+D+i Agency — candidate genes

 

🇦🇷 ARGENTINA TRIGUERA

A discovery with a Pampean name and surname

Argentina is not only a wheat-producing country: it is one of the great breadbaskets of the world. With an average production of 19 million tonnes per year, wheat is the country's second most important winter crop after barley, and one of the pillars of national agri-food exports.

Of those 19 million tons, between six and seven million are consumed domestically – in the form of bread, noodles, semolina and multiple derivatives – while the rest is exported. Advancing the potential yield of the crop, even by one percentage point, has a direct economic impact on millions of dollars in foreign exchange and on the food security of countries that depend on Argentine imports.

"Advancing in basic and technological knowledge that allows us to increase crop yields in a more efficient and sustainable way could, firstly, improve national production and exportable balances and, secondly, contribute to global food security," said González when presenting the results.

 

"This line of work began more than fifteen years ago, when we identified the reproductive efficiency of the ear as a promising trait to improve wheat yield, particularly in Argentine varieties." — Fernanda González — CONICET / CIT NOBA / INTA Pergamino

 

🏭 PRACTICAL APPLICATIONS

Seedbeds, fields and technology: science comes out of the laboratory

One of the most outstanding aspects of the finding is its immediate applicability. Unlike many genomic discoveries that remain in the experimental stage for years, the QTLs identified by the team are tools that can be integrated into conventional breeding programs today, without the need for gene editing or state-of-the-art technologies.

In the short term: Wheat breeding companies can use identified QTLs to perform molecular marker-assisted selection at early stages. This means crossing varieties and, through a simple DNA analysis, identifying which of the hundreds of resulting plants carry the favorable allele, without the need to wait for harvest.

In the medium term: the team is working on identifying the specific genes that are within the QTL regions. Once these genes are known, new doors are opened: precision genetic editing, improvement of varieties with greater climatic adaptation, and multiplication of the effect in combination with other agronomic characteristics.

🔓 PUBLIC DATA, FREE ACCESS FOR ALL COMPANIES ✅  The data of the identified QTLs are freely accessible and are already available to all companies in the sector through CONICET. 🤝  Several breeding companies have already contacted the team to begin applying the results in their selection programs. 🎓  Giuliana Ferrari, a doctoral fellow at the R+D+i Agency, joined the team to continue identifying the specific genes within the key regions.

 

"The identified QTLs could be used to select lines during the breeding process, with the aim of obtaining wheat varieties with higher yields," Vanzetti explained. He added that the long term is also promising: "This would allow us to understand in greater depth some of the mechanisms that regulate performance and would open the doors to applying new breeding technologies, such as gene editing."

 

🌱 BEYOND WHEAT

Barley, rice, corn: the scope of a cross-sectional finding

One of the aspects that most excites the scientific community is the possibility that the mechanisms identified in wheat are not exclusive to this species. Many processes that determine yield in cereals are evolutionarily conserved: similar genes can serve analogous functions in wheat, barley, rice, and maize.

"What we found in wheat may provide clues to investigate similar mechanisms in crops such as barley, rice or corn. In fact, within the region of the genome that we identified, we found candidate genes whose function has already been described in other crops, which reinforces the idea that these are conserved mechanisms. This opens the door to comparative studies and more integrated breeding strategies between species," Pretini said.

In practical terms, this means that the Argentine find could become the seed of a new generation of research into crops that feed billions of people around the world. Rice is the basis of the diet in Asia; maize is essential in Latin America and Africa; Barley is key to beer and animal feed. If the same QTLs identified in wheat have functional analogues in those species, the potential impact is multiplied exponentially.

 

🕰️ THE STORY BEHIND THE DISCOVERY

Fifteen years of patient science

 

2007	The INTA Pergamino team, led by Fernanda González, begins to study the reproductive efficiency of the ear as a promising characteristic for wheat yield. First working hypothesis.
2012	First results in trials at the individual plant scale. Patterns in wheat DNA related to fruiting are identified. The team is consolidated with the incorporation of researchers from INTA Marcos Juárez.
2018	Formal identification of QTLs QFFE.perg-5A and QFEm.perg-3A under controlled conditions. The markers are named and larger-scale validation studies begin.
2021	INTA Informa publishes the team's advances on the physiology and genetics of spike fertility. The work is beginning to arouse interest in the seed companies of the private sector.
2025	🌟 Publication in Field Crops Research: QTLs are validated in real field conditions, with consistent impact in multiple environments. Giuliana Ferrari joins in to identify specific genes. Seed companies are beginning to apply the results.

 

✍️ EDITORIAL

An ear that holds more than grains

In a country accustomed to celebrating its natural advantages in agricultural production, this finding reminds us that the real competitive advantage of the future is not only in the quality of the soils or in the climate of the humid pampas. It is in knowledge: in the quiet work of scientific teams that for fifteen years pursued a difficult question in university laboratories, experimental stations and borrowed lots.

The work of Pretini, González and Vanzetti is, in this sense, a model of applied science with real impact. They are not just looking to publish; They want seed companies to use their results, so that the varieties planted in the next decade are more efficient, so that each hectolitre exported represents more grains and more foreign exchange. And that, in the long term, this knowledge will also serve to better feed a planet that in 2050 will have 10,000 million mouths.

An ear of wheat, seen from the outside, is almost invisible in the immensity of the pampas. But inside their cells, a handful of genes contain the difference between a mediocre harvest and an exceptional one. Argentine science has just found some of these genes. Now, the challenge is not to let that knowledge get lost in an academic journal and I really got to the fields.

 

Tags: 🌾 Wheat 🧬 Genomics 🔬 CONICET 🌿 INTA 🇦🇷 Science Argentina 🌍 Food 📊 Safety Field Crops Research

© 2026 — Sources: CONICET, INTA Informa, Field Crops Research, La Nación, Infobae Revista Chacra, Agencia DIB, Radio Nacional.

CONICET researchers achieved a high-impact scientific breakthrough: they demonstrated that synchronized stimulation with intermittent light and sound can promote the generation of new neurons in aging brains, strengthening the hippocampus and opening perspectives for the treatment of Alzheimer's and other neurodegenerative diseases.

🧠 The scientific finding

• Participating institutions: CONICET and Leloir Institute Foundation.
• Methodology: application of intermittent visual and auditory stimuli, synchronized in gamma frequency.
• Results: In animal models, the integration of new neurons into brain circuits was observed, especially in the hippocampus, a key region for memory and learning.

🔑 Relevance of the discovery

• Neurogenesis in aged brains: it was proven that even at advanced ages it is possible to regenerate neurons.
• Strengthening of the hippocampus: the technique reinforces the neural circuits affected in Alzheimer's.
• Non-invasive alternative: synchronised audiovisual stimulation is emerging as an accessible and safe tool.
• Potential impact: It  could become a complementary approach to slow cognitive decline.

📊 Medical and social implications

Area	Expected impact
Alzheimer's	Possible partial restoration of cognitive functions
Brain aging	Improved plasticity and memory
Clinical research	Basis for future human trials
Accessibility	Non-invasive, low-cost and replicable method

⚠️ Challenges and next steps

• Validation in humans: so far the results are preclinical, in mice.
• Scalability: it is necessary to adapt the technique to real clinical contexts.
• Regulation and ethics: any therapeutic application must pass safety and efficacy tests.

🎙️ Conclusion

The CONICET study marks a milestone in Argentine neuroscience. With an innovative approach, the researchers showed that the combination of light and sound can reactivate the brain's ability to generate neurons, even in stages of aging. This finding opens a path of hope in the face of Alzheimer's, a disease that affects millions of people in the world.